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Background: Expression profile of the toll like receptors (TLRs) on PBMCs is central to the regulation of
proinflammatory markers. An imbalance in the TLRs expression may lead to several types of inflammatory disorders.
Furthermore, the dynamic regulation of inflammatory activity and associated impaired production of cytokines by
peripheral blood mononuclear cells (PBMCs) in obese individulas remain poorly understood. Therefore, we
determined the perturbation in TLRs (TLR2 and TLR4), their adaptor proteins (MyD88, IRAK1 and TRAF6) expression
in PBMCs/subcutaneous adipose tissue (AT) as well as inflammatory cytokines changes in obese individuals.
Methods: mRNA expression levels of TLR2, TLR4, IL-6, TNF-α and adaptor proteins were determined by RT-PCR.
TLR2, TLR4 and adaptor proteins expression in AT was determined by immunohistochemistry.
Results: Obese and overweight individuals showed significantly increased expression of TLR2, TLR4 and MyD88 in
both PBMCs and AT as compared with lean individuals (P < 0.05). Interestingly, we found a remarkably higher
expression of TLRs in obese and overweight individuals with type 2 diabetes (P < 0.05). Increased expression of
TLR2, TLR4, MyD88 and IRAK1 correlated with body mass index (BMI) (TLR2: r = 0.91; TLR4: r = 0.88, P <0.0001;
MyD88: r = 0.95, P < 0.0001; IRAK1 r = 0.78, P < 0.002). TLRs’ expression was also correlated with fasting blood
glucose (FBG) (TLR2: r = 0.61, P < 0.002; TLR4: r = 0.52, P < 0.01) and glycated haemoglobin (HbA1c) ( TLR2: r = 0.44,
P <0.03; TLR4: r = 0.48, P < 0.03). Transcript levels of IL-6 and TNF-α were highly elevated in obese subjects
compared to lean subjects. There was a strong association of TLRs’ expression in PBMCs with TNF-α (TLR2: r = 0.92;
TLR4: r = 0.92; P < 0.0001) and IL-6 (TLR2: r = 0.91, P < 0.0001; TLR4: r = 0.81; P < 0.001). Similarly adaptor proteins
were significantly correlated with TNF-α (MyD88: r = 0.9, P < 0.0001; IRAK1: r = 0.86; P < 0.0002) and IL-6 (MyD88:
r = 0.91, P < 0.0001; IRAK1: 0.77; P < 0.002).
Conclusions: TLRs and adapter proteins were overexpressed in PBMCs from obese subjects, which correlated with
increased expression of TNF-α and IL-6. This association may explain a potential pathophysiological link between
obesity and inflammation leading to insulin resistance.Introduction
Obesity is associated with a low-grade systemic chronic
inflammation that is linked to insulin resistance, car-
diovascular diseases and type-2 diabetes [1-3]. Obesity-
induced inflammation is characterized by the abnormal
production of pro- and anti-inflammatory adipocyto-
kines. It has been found that resident macrophages in* Correspondence: rasheed.ahmad@dasmaninstitute.org
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reproduction in any medium, provided the oradipose tissue are mainly responsible for the produc-
tion of inflammatory cytokines. The dynamic regula-
tion of inflammatory activity and associated impaired
production of cytokines/chemokines by PBMCs and
adipocytes from obese individuals remain poorly
understood. Changes in the expression profile of differ-
ent receptors, ligands and adhesion molecules on
PBMCs may lead to the development of different im-
munological diseases.
TLRs are transmembrane proteins involved in detec-
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family in mammals (11 members in human) are known
so far [4]. Structurally, TLRs are characterized by an
extracellular leucine-rich repeat (LRR) domain, a domain
involved in the recognition of pathogen-associated mo-
lecular patterns (PAMPs) and a cytoplasmic Toll/IL-1
(TIR) domain that activates downstream signaling mole-
cules including MyD88, IRAKs and TRAF6 [5]. Activa-
tion of these adaptor proteins stimulates multiple
cascades including extracellular signal-regulated kinase
(ERK), c-Jun N-terminal kinase (JNK) and p38
mitogen-activated protein kinases (MAPK) pathways
and activation of NF-kB signaling and the resulting
up-regulation of diverse inflammatory mediators, such
as cytokines, chemokines, and adhesion molecules,
which together, serve essential functions in promoting
inflammation. Increased activity of TLR2 and TLR4
has been found in diabetic patients and is associated
with the pathogenesis of diabetes and atherosclerosis
in both clinical and experimental conditions [6-9].
TLR2 and TLR4 bind to components of the Gram-
positive and -negative bacteria, respectively [10]. In
addition, ligands for TLR2 and TLR4 include free fatty
acids, high-mobility group B1 protein (HMGB1), heat
shock protein-60 (HSP60), heat shock protein-70
(HSP70), endotoxin, hyaluronan, advanced glycation
end (AGE) products, and extracellular matrix compo-
nents [10].
The role of TLR2 and TLR4 has been suggested in
conventional insulin resistance (IR) target tissues like
skeletal muscle and adipose tissue of Type 2 diabetes
subjects [11,12]. TLR4 was described as a molecular link
between free fatty acids, inflammation, and the innate
immune system [6]. High TLR4 mRNA expression was
reported in differentiating adipose tissue of db/db mice
[13]. Adipocytes produced IL-6 via TLR4 activation and
the upregulation of osteopontin further exacerbated adi-
pose tissue inflammation and insulin resistance [14].
While these important observations from animal and
human tissue data create an interest to see a role for
TLR2 and TLR4 in obesity, it remains unknown whether
alterations in TLR2 and TLR4 expression and associated
inflammatory cytokines contribute to systemic inflam-
mation which causes induction of insulin resistance in
obese individuals. Therefore, we determined the changes
in expression of TLRs in PBMCs/AT and associated in-
flammatory cytokines (TNF-α and IL-6) in obese indivi-
duals. We found elevated expression of TLRs and their
adaptor proteins in PBMCs and AT. Elevated expres-
sion of TLRs and their adaptor proteins were signifi-
cantly correlated with inflammatory cytokines. The
localization of TLRs in adipose tissue was confirmed by
immunohistochemistry. This study supports a model
where the increased TLRs’ expression relates with theelevated cytokine expression in PBMCs from obese
subjects.
Methods
Study Participants and clinical laboratory evaluation
43 individuals were recruited from the local clinics.
Written informed consent was obtained from all partici-
pants for inclusion in the study and the study protocol
was approved by the institutional ethics committee (Eth-
ical Review Committee of Dasman Diabetes Institute).
Lean, overweight and obese subjects are asymptomatic
or free of disease. Diabetic subjects were on medication
of glucophage alone or in combination with crestor or
zestril or januvia. Blood samples were collected after
overnight fasting for isolation of PBMCs and for the de-
termination of blood-derived factors including blood
glucose, total cholesterol, high density lipoprotein chol-
esterol (HDL-C), low-density lipoprotein cholesterol
(LDL-C), and hemoglobin A1c (HbA1c). Participants’
age, height, weight, blood pressure and diabetes status
were assessed at the time of the blood draw. All bio-
chemical tests were performed by using standard kits.
The characteristics of the participants are described in
Table 1. Adipose tissue samples were obtained from 21
individuals with different BMI.
Peripheral blood mononuclear cells (PBMCs)
For PBMCs isolation, fresh blood samples were collected
from participants in EDTA-tubes. PBMCs were isolated
by using Ficoll-Hypaque density gradient centrifugation
[15].
Subcutaneous adipose tissue biopsy
Human adipose tissue samples were collected via ab-
dominal subcutaneous fat pad biopsy lateral to the um-
bilicus using standard surgical techniques. In brief, the
region was sterilized using alcohol, and locally anesthe-
tized with 2 ml 2% lidocaine. Through a small superficial
0.5 cm skin incision, fat tissue was collected via punch
biopsy. Tissue samples were stored in formalin or snap-
frozen in liquid nitrogen and stored at −80°C. Samples
were then used for immunohistochemical staining.
Immunohistochemistry
Frozen sections (4 μm) of adipose tissue were cut. Slides
were deparaffinized in xylene and rehydrated in pure
ethanol to water. Antigen retrieval was done by placing
the slides in target retrieval solution pH6.0 (Dako) in the
pressure cooker boiling for 8 minutes and cooling down
for 15 minutes. After washing in phosphate buffer saline
(PBS), endogenous peroxidase was blocked with 3%
H2O2 for 30 minutes. The slides were blocked with 5%
milk for 1 hour followed by the 1 hour incubation with
1%BSA solution. The slides were incubated in primary
Table 1 Characteristics of the study participants
Characteristic Lean Overweight Obese
Non-Diabetic Diabetic Non-Diabetic Diabetic Non-Diabetic Diabetic
Age range (years) 25-48 41-53 28-52 42-63 29-57 27-58
Body mass index 23.19 ± 1.27 23.71 ± 0.97 28.23 ± 1.16 27.99 ± 0.71 34.71 ± 2.97 32.73 ± 2.45
Fasting blood glucose (mmol/l) 5.00 ± 0.77 9.40 ± 5.37 5.04 ± 0.47 9.46 ± 2.55 5.73 ± 0.95 9.70 ± 3.04
Glycosylated haemoglobin (%) 5.73 ± 0.98 9.85 ± 1.90 5.52 ± 0.56 9.35 ± 2.73 5.84 ± 0.65 8.12 ± 1.61
Cholesterol (mmol/l) 4.85 ± 0.94 4.70 ± 15 4.80 ± 0.73 4.61 ± 0.57 5.33 ± 1.06 5.71 ± 0.90
HDL cholesterol (mmol/l) 1.27 ± 0.31 1.17 ± 0.41 1.18 ± 0.17 1.40 ± 0.47 1.13 ± 0.24 1.07 ± 0.13
LDL cholesterol (mmol/l) 3.05 ± 0.81 2.95 ± 1.48 3.10 ± 0.68 2.52 ± 0.22 3.80 ± 2.25 3.25 ± 0.70
Triglycerides (mmol/l) 1.12 ± 0.67 1.24 ± 0.95 1.14 ± 0.72 1.48 ± 0.99 1.97 ± 1.13 2.95 ± 1.12
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tion of rabbit polyclonal TLR-2 antibody (ProSci Incor-
porated), 1:400 dilution of rabbit polyclonal TLR-4
antibody (ProSci Incorporated), 1:200 dilutions of rabbit
polyclonal antibody (ProSci Incorporated), 1:200 dilution
of TRAF6 antibody (ProSci Incorporated), 1:200 dilution
of MyD88 (ProSci Incorporated) and 1:200 dilution of
IRAK antibody (ProSci Incorporated). After washing
with PBS–0.05% Tween, slides were incubated for 1 hour
with the respective secondary antibodies. Bound anti-
body was detected with HRP EnVision Plus Kit. Color
was developed in 3, 3’-diaminobenzidine chromogen
substrate. The sections were then washed in running tap
water, lightly counterstained with Gill’s hematoxylin,
dehydrated through ascending graded alcohols, cleared
in xylene, and mounted in DPX. Two different observers
who were blinded to the source of the tissues quantified
the expression of each antigen semiquantitatively on a 3-
point scale, where 0 = no staining; 1 = mild expression,
limited areas stained; and 3 = strong expression, strong
overall staining. Immunohistochemical staining of the
section of human spleen tissue (HST) was used as posi-
tive control for TLR2. Immunohistochemical staining of
the section of breast cancer tissue was used as positive
control for TLR4 [16].
Reverse Transcription Polymerase Chain Reaction
Total RNA was extracted using RNeasy kit (Qiagen).
The cDNA was synthesized with 0.5ug of total RNA
using high capacity cDNA reverse transcription kit
(Invitrogen). Polymerase chain reaction (PCR) was per-
formed using the One Step PCR kit (Promega). The primer
pairs used were as follows: TLR2 Fwd (50-ATTGTGCCCA
TTGCTCTTTC-30) and TLR2 Rev (50-TTCTTCCTTGGA
GAGGCTGA −30); TLR4 Fwd (50-AATCCCCTGAGGCAT
TTAGG-30) and TLR4 Rev (50-CCCCATCTTCAATTGTC
TGG −30); MyD88 Fwd (50-GGATGGTGGTGGTTGTCT
CT-30) and MyD88 Rev (50-AGGATGCTGGGGAACTCTTT-30); IRAK1 Fwd (50- AGCCCCTTCTTCTACCAAGC-
30) and IRAK1 Rev (50-AGGAAGCTCTGCTTCACTGC-
30) TRAF6 Fwd (50-CTGCAAAGCCTGCATCATAA-
30) and TRAF6 Rev (50- GGGGACAATCCATAAGAGC
A −30); TNF-α Fwd (50-CAGAGGGCCTGTACCTCAT
C-30) and TNF-α Rev (50- GGAAGACCCCTCCCAGA
TAG −30); IL-6 Fwd (50- CAGGGGTGGTTATTGCAT
CT-30) and IL-6 Rev (50-AAAGAGGCACTGGCAGAA
AA-30) and GAPDH Fwd (50-ATCGTGGAAGGACTCAT
GACCACA-30) and GAPDH Rev 50-TAGAGGCAGGGAT
GATGTTCTGGA-30. The RNA was reverse-transcribed
at 50°C for 30 minutes and reverse transcriptase was inac-
tivated at 95°C for 15 minutes. PCR was run at: 30 cycles
of 94°C for 1 minute, 50°C for 1 minute, 72°C for 1 minute,
and a final extension step at 72°C for 10 minutes. The PCR
product (10 μl) was analyzed on 1.4% agarose gel to detect
TLR2, TLR4, MyD88, IRAK1, TRAF6, IL-6, TNF-α and
GAPDH cDNA amplification. Relative band quantification
was performed by using Gel Doc™ XR+ imaging system
(Bio Rad,USA). Density of the bands was expressed in arbi-
trary units. Jurkat cells were used as a –ve control for TLR2
and TLR4 [17]. THP1 cells were used for + ve control for
TLR2 and TLR4 [18].
Statistical analysis
Data were presented as mean ± standard deviation, unless
otherwise indicated. Unpaired Student t test was used to
compare means between groups. Correlation and linear
regression were used to see the association between differ-
ent variables. For all analyses, P value < 0.05 was consid-
ered significant. All statistical analysis was performed with
GraphPad Prism software (La Jolla, CA, USA).
Results
Elevated expression of TLRs in PBMCs from
obese subjects
Peripheral blood mononuclear cells (PBMCs) are of-
ten considered for investigating many aspects of
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been shown that TLR2 and 4 are highly expressed in
PBMCs during course of inflammatory disorders. How-
ever, since expression of TLR2 and 4 in PBMCs in obes-
ity has yet not been well defined, we measured levels of
mRNA for TLR2 and 4 in PBMCs from obese, over-
weight and lean individuals. As shown in Figure 1A,
TLR2 mRNA showed the highest expression, followed
by TLR4 in obese subjects and there was significant
difference from lean subjects (P < 0.05). Significant differ-
ences in the expression of TLRs were also found between
overweight and lean subjects (P < 0.05) (Figure 1B, C).Figure 1 Expression of TLR2 and TLR4 mRNA in PBMCs. The PBMCs fro
for total RNA isolation. TLR2 and TLR4 mRNA were measured by RT-PCR. Ju
express TLR2 and TLR4 (+ve control) (A). The RNA expression was normaliz
expression is shown in arbitrary units for each group. Results are expressed
means ± SE values (B and C). A strong association of TLR2/ TLR4 mRNA witExpression levels of TLRs increased significantly with
increasing BMI (TLR2: r = 0.91; TLR4: r = 0.88, P < 0.0001)
(Figure 1D, E).
Elevated expression of adaptor proteins in PBMCs from
obese subjects
TLRs’ activation requires the signal transduction molecules
myeloid differentiation protein (MyD88), IL-1 receptor-
associated kinase 1(IRAK1), and tumor necrosis factor
(TNF) receptor-associated kinase 6 (TRAF6) which led
to the hypothesis that these TLR’s adaptor proteins
(MyD88, IRAK1 and TRAF6) could be increased inm 4 individuals in each group (lean, overweight and obese) were used
rkat cells do not express TLR2 and TLR4 (−ve control). THP1 cells
ed to GAPDH housekeeping gene expression. TLR2 and TLR4 mRNA
relative to the expression level in controls and are represented as
h BMI was observed in PBMCs (D and E).
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pression of TLRs’ adaptor proteins MyD88, IRAK1 and
TRAF6 in PBMCs used in the previous experiment. We
found that expression levels of MyD88 and IRAK1 were
significantly increased in PBMCs from overweight and
obese subjects (P < 0.05) (Figure 2A, B, C). However we
noticed a strong constitutive expression of TRAF6 in
PBMCs from all groups of subjects (Figure 2A, D). Linear
regression analysis revealed a significantly positive correl-
ation between MyD88/IRAK1 expression and BMI
(MyD88: r = 0.95, P < 0.0001; IRAK1: r = 0.78, p < 0.002)
(Figure 2E, F). No association was observed between
TRAF6 expression and BMI (Figure 2G).Figure 2 Expression of TLRs’ adaptor proteins in PBMCs. The PBMCs fr
used for total RNA isolation. MyD88, IRAK1 and TRAF6 mRNA were measure
housekeeping gene expression. MyD88, IRAK1 and TRAF6 mRNA expression
relative to the expression level in controls and are represented as means ±
BMI was observed in PBMCs (E and F).TLRs and MyD88 are upregulated in subcutaneous
adipose tissue from obese subjects
To identify TLR2 and TLR4 expression in adipose tis-
sues, we performed immunohistochemical analysis of
the sections from 21 subjects (lean 6; overweight 7;
obese 8) that were stained with the respective antibodies.
Staining intensity of TLR2 and TLR4 expression was
greater (P < 0.05) in obese subjects compared to lean or
overweight subjects (Figure 3A, B, D and E). It was
noticed that staining intensities of TLR2 and TLR4 were
observed in the areas of the adipose tissue infiltrated
with inflammatory cells. TLR2 and TLR4 positive cells
were more abundant in adipose tissue section fromom 4 individuals in each group (lean, overweight and obese) were
d by RT-PCR (A). The RNA expression was normalized to GAPDH
is shown in arbitrary units for each group. Results are expressed
SE values (B, C and D). A strong association of MyD88 and IRAK1 with
Figure 3 Expression of TLR2 and TLR4 in adipose tissues. Sections of the adipose tissues from individuals (Obese 8; Overweight 7 and 6
Lean) were stained with TLR2, TLR4 or with control antibodies . All sections were counterstained with hematoxylin. Positive signals appear in red
(original magnification X100). Two representative sections of the adipose tissues from each group were shown. Arrowheads indicate intensity of
the expression of TLR2 and TLR4 on the cells (A & D). Intensity of expression was assessed and an expression score was assigned according to
following scale: 0 (no staining) and 3 (strong staining). Horizontal bars show the mean (B & E). Correlation and simple linear regression of AT
expression of TLR2 and TLR4 with BMI was observed (C and F). Isotype –ve control (G). Section of human spleen tissue (HST); positive control for
TLR2 (H). Section of breast cancer tissue (BCT); positive control for TLR4 (I).
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and D). Linear regression analysis also revealed a sig-
nificantly positive correlation between TLR2/TLR4
expression levels and BMI (TLR2: r = 0.68, P = 0.0007;
TLR4: r = 0.43, P = 0.052) (Figure 3C and F). We alsomeasured the expression of TLRs’ adaptor proteins
MyD88, IRAK1 and TRAF6 in adipose tissues used in
the previous experiment. We found that only MyD88
levels were increased in adipose tissues from obese indi-
viduals (Figure 4A, B). Linear regression analysis
Figure 4 Expression of MyD88 in adipose tissues. Sections of the adipose tissues from individuals (Obese 8; Overweight 7 and 6 Lean) were
stained with MyD88 or with control antibodies . All sections were counterstained with hematoxylin. Positive signals appear in red (original
magnification X100). Two representative sections of the adipose tissues from each group were shown. Arrowheads indicate intensity of the
expression of MyD88 on the cells (A). Intensity of expression was assessed and an expression score was assigned according to following scale: 0
(no staining) and 3 (strong staining). Horizontal bars show the mean (B). Correlation and simple linear regression of AT expression of MyD88 with
BMI was observed (C). Isotype –ve control (D). Section of BCT; positive control for MyD88 (E).
Ahmad et al. Journal of Inflammation 2012, 9:48 Page 7 of 11
http://www.journal-inflammation.com/content/9/1/48revealed a significantly positive correlation between
MyD88 protein expression and BMI (r = 0.58, P = 0.005)
(Figure 4C).
Increased expression of TNF-α and IL-6 is correlated with
TLRs’ expression in PBMCs of obese subjects
It has been known that elevated circulating levels of
TNF-α and IL-6 in obese subjects play an important role
in the development of insulin resistance [19-22]. How-
ever, less information is available about the simultaneous
expression of TNF-α and IL-6 with TLRs in PBMCs
from same individuals. Therefore, we investigated the
expression of these cytokines in the PBMCs and their
association with the expression of TLRs and their
adaptor proteins. Transcript levels of TNF-α and IL-6
were significantly higher in PBMCs from overweight and
obese subjects compared to lean subjects (P < 0 · 05)
(Figure 5A, B, C). Linear regression analysis demon-
strated an association between the transcript expression
levels of cytokines and TLRs expression (TLR2 vs TNF-
α: r = 0.92, P < 0.0001; TLR2 vs IL-6: r = 0.91, P < 0.0001;
TLR4 vs TNF-α: r = 0.92, P < 0.0001; TLR4 vs IL-6: r =
0.81, P < 0.001) (Figure 5D, E). The increased expression
of TNF-α and IL-6 in PBMCs from obese subjectscorrelated with increased expression of TLRs’ adaptor pro-
teins (MyD88 vs TNF-α: r = 0.9, P < 0.0001; MyD88 vs IL-6:
r = 0.91, P < 0.0001; IRAK1 vs TNF-α: r = 0.86, P < 0.0002;
IRAK1 vs IL-6: r = 0.77, P < 0.002) (Figure 5F, G).
Expression of TLRs in PBMCs from obese subjects with
type 2 diabetes
Since our data showed that TLRs expression was high
in obese individuals and was significantly correlated
with inflammatory cytokines which causes insulin re-
sistance. Therefore, we measured TLRs’ expression in
PBMCs from 10 diabetic subjects with different BMI.
Our results showed that the subjects with type-2 dia-
betes had significantly elevated mRNA levels of TLR2
and TLR4 as compared with non-diabetic obese sub-
jects (Figure 6A, B and Figure 1A). The basal levels of
TNF-α and IL-6 were high in all groups of diabetic
subjects and there was no significance difference (data
not shown).
Increased TLRs’ expression is correlated with FBG
and HbAIc
Spearman’s rank correlation was performed to assess the
association of TLRs’ expression with FBG and HbAIc.
Figure 5 Expression of IL-6 and TNF-α in PBMCs. The PBMCs from 4 individuals in each group (lean, overweight and obese) were used for
total RNA isolation. IL-6 and TNF-α mRNA were measured by RT-PCR (A). The RNA expression was normalized to GAPDH housekeeping gene
expression. Cytokines expression is shown in arbitrary units for each group. Results are expressed relative to the expression level in controls and
are represented as means ± SE values (B and C). A strong association of TLR2/ TLR4 mRNA with cytokines was observed in PBMCs (D and E). A
simple linear regression analysis indicated a significant positive association between adopter protein (MyD88 or IRAK1) and cytokines (F and G).
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in obesity was significantly correlated with FBG (r = 0.61;
P < 0.0025) and HbAIc (r = 0.44; P < 0.03) (Table 2).
Similarly, TLR4 positively correlated with FBG (r = 0.52;
P < 0.01) and HbAIc (r = 0.48; P < 0.03) (Table 2).
Discussion
Obesity is associated with a low-grade systemic chro-
nic inflammatory state characterized by abnormal pro-
duction of pro- and anti-inflammatory adipocytokines
leading to immune dysfunction and contributing
to increased disease risk. Precise triggers for obesity-
induced inflammation are not yet fully understood. Ac-
tivation of PBMCs is an important initial step in the
cascades of events leading to many inflammatorydiseases including insulin resistance. Since expression of
receptors on cells is a key element in the regulation of
proinflammatory cytokines, we determined whether
TLRs (TLR2 and TLR4) and inflammatory cytokines ex-
pression was simultaneously modulated on PBMCs in
obesity.
Our data demonstrated alterations in TLR2 and TLR4
expressions in PBMCs and adipose tissues from obese
subjects. In parallel, abnormalities in cytokines expres-
sion were found in PBMCs from obese individuals.
Moreover, we found that there was a strong association
between TLRs’ expression and cytokines (IL-6 and TNF-α)
measured simultaneously in PBMCs. Recent findings
indicate that the TLRs which are up-regulated in the
affected tissue of most inflammatory disorders can
Figure 6 Expression of TLRs in subjects with type 2 diabetes. PBMCs from 10 individuals with diabetes (lean: 2; overweight: 4; obese: 4) were
used for total RNA isolation. TLR2/TLR4 mRNA was measured by RT-PCR (A). The RNA expression was normalized to GAPDH housekeeping gene
expression. TLRs’ expression is shown in arbitrary units for each group. Results are expressed relative to the expression level in controls and
horizontal bars show the mean of each group. The values of expression of TLRs in PBMCs from 12 non diabetic subjects were taken from
Figure 1 (B and C).
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body metabolism [23]. Increased TLRs activity was
reported in patients with metabolic syndrome [24]. Ele-
vated TLR2 and TLR4 expression was assessed in
artherosclerotic lesions [25]. Higher expression of TLRs
3 and 4 in other conditions, such as an early stage of
RA suggests that modulation in TLR expression does
result during inflammatory states [26]. We found that
markedly increased TLR2 and TLR4 levels in adipose
tissue from obese subjects related with their increased
expression on PBMCs. This could be the result ofTable 2 Correlation of TLRs with Fasting Blood Glucose
and HbA1c
TLRs Metabolic parameters Spearman r P
TLR2 Fasting Blood Glucose (mmol/l) 0.6107 0.0025**
HbA1c 0.442 0.039*
TLR4 Fasting Blood Glucose (mmol/l) 0.52 0.01*
HbA1c 0.48 0.03*migration of inflammatory monocytes/macrophages
from the peripheral compartment to the adipose tissue.
Shi et al. (2006) argued that the increased expression of
TLR4 mRNA in total adipose tissue extracts in two
models of obesity could be due, in part, to increased
numbers of macrophages known to reside in fat tissue
of obese animals. Since a preferential macrophage infil-
tration into obese adipose tissue was demonstrated
[27], it was suggested that the toll-like receptors’ ex-
pression in adipose tissue was mainly due to macro-
phages [28].
The enhanced expression of cytokines we observed in
obese subjects could be explained by an elevated expres-
sion of TLRs on PBMCs. Other factors, such as
increased free fatty acids, can influence TLRs responsive-
ness and explain the increased response observed in
obese individuals. Saturated free fatty acids which are
elevated in case of obesity are able to augment TLR
induced cytokine production [29,30]. This could be a
reason, in part, that obese individuals are more prone to
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tween TLR activation and insulin resistance. Free fatty
acids cause insulin resistance in TLRs dependent man-
ner. Recently pro-inflammatory effects of resistin were
seen through its activation of TLR4 [31] and other en-
dogenous ligands such as HMGB1 or hyaluronan frag-
ments or HSPs also served as TLR4 or TLR2 activators
[32]. Mice lacking TLR2 are substantially protected from
diet-induced adiposity, insulin resistance, hypercholes-
terolemia, and hepatic steatosis and TLR2 deletion was
associated with attenuation of adipocyte hypertrophy as
well as diminished macrophage infiltration and inflam-
matory cytokine expression [33]. It was reported that the
absence of TLR2 attenuated local inflammatory cytokine
expression and related signaling and increased insulin
action specifically in the liver [34]. Notably, only a few
studies so far have described the responsiveness of TLRs
to free fatty acid in insulin resistance and cytokine pro-
duction. Interestingly, TLR expression modulation on
PBMCs and adipose tissues in obese individuals remains
poorly defined. The present data show over-expression
of TLR2 and TLR4 on both PBMCs and adipose tissues
which may explain their increased response to endogen-
ous TLR ligands. Our findings suggest that TLRs modu-
lation is linked with expression of proinflammatory
cytokines in obese individuals.
The prior data demonstrate a correlation between
TLR2/4 expression and BMI in subjects with type 2 dia-
betes [30]; however, the exact mechanism by which these
two clinical predictors are interlinked remains un-
defined. There is lacking information about the relation
of TLRs modulation and BMI in obese individuals. Ex-
pression of TLR2 and TLR4 on PBMCs varied widely
among the individuals with different BMI that we
observed. The extent of the obesity-induced up-regula-
tion of TLR2/TLR4 genes and related proinflammatory
cytokines cascades related to the BMI values. We found
that TLR2 and TLR4 and inflammatory cytokines were
overexpressed in PBMCs from obese subjects and this
TLRs/cytokines overexpression correlated with the BMI.
Increased expression of TLRs was correlated with FBG
and HbAIc. More importantly, our data show a remark-
able difference in the level of expression of toll-like
receptors between obese individuals with and without
diabetes. Overall, these results suggest that the overex-
pression of TLR2 and TLR4 on both PBMCs and adi-
pose tissues together with the enhanced production of
proinflammatory cytokines may pave way for the devel-
opment of insulin resistance in obese individuals, leading
to type 2 diabetes.
In conclusion, we found that TLR2 and TLR4 were
overexpressed on PBMCs/adipose tissues from obese
subjects which correlated with the increased expression
of proinflammatory cytokines. This association mayexplain a potential pathophysiological link between
obesity and inflammation, to subsequently result in de-
velopment of insulin resistance and type 2 diabetes.
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